Mostrando 4 resultados de: 4
Filtros aplicados
Origen
scopus(4)
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia
ArticleAbstract: Context: Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic gPalabras claves:adrenal hypertrophy, ATR-101, Clinical trial, Congenital adrenal hyperplasia, nevanimibeAutores:Chang A.Y., El-Maouche D., Joyal E.G., Lin V.H., Merke D.P., Mohideen P., Plaunt M.R., Richard J. Auchus, Turcu A.F., Vogiatzi M.G., Weintraub L.Fuentes:scopusCorrection to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies (The Journal of Clinical Endocrinology and Metabolism (2021) 106:11 (e4666-e4679) DOI: 10.1210/clinem/dgab438)
OtherAbstract: Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200Palabras claves:Autores:Barnes C.N., Huang M., Imel E.A., Madu I.J., Merke D.P., Moriarty D., Nakhle S., Newfield R.S., Richard J. Auchus, Sarafoglou K., Vogiatzi M.G.Fuentes:scopusErratum: Global disorders of sex development update since 2006: perceptions, approach and care (Hormone Research in Paediatrics (2016) 85 (158-180) DOI: 10.1159/000442975)
OtherAbstract: In the appendix of the recent publication by Lee et al. entitled 'Global disorders of sex developmenPalabras claves:Autores:Ahmed S.F., Ansermet F., Baker L., Baratz A., Baskin L., Belgorovsky A.V., Berenbaum S.A., Bouvattier C., Braga L., Caldamone A., Callens N., Charmandari E., Chigiti J.M., Cohen-Kettenis P.T., Conte F., Conway G.S., Cools M., Dalke K.B., Davis G., Delimata N., Di Grazia M., Drop S.L.S., Duranteau L., Ediati A., El Ghoneimi A., Flück C.E., Garland J., Gay C.L., Gillam L., Gorduza D., Green J., Guerra G., Hensle T., Hines M., Hoebeke P., Horikawa R., Houk C.P., Kaefer M., Kaggwa J.K., Kalfa N., Karkazis K., Kolon T., Lee M.M., Lee P.A., Lesma A., Liao L.M., Lin-Su K., Loke K.Y., Looijenga L.H.J., Manzoni G., Marrocco G., Mazur T., Merlini E., Meyer-Bahlburg H.F.L., Moore J., Mouriquand P., Muscarella M.B., Nordenskjold A., Nordenström A., Poppas D.P., Quigley C.A., Ransley P., Rey R., Richard J. Auchus, Rigamonti W., Rink R., Rivarola M., Roen K., Romao R., Rossi W., Salle J.L.P., Sandberg D.E., Sann L., Schober J.M., Sibai H., Smith A., Srinivasan S., Sudai M., Sultan S., Vilain E., Vogiatzi M.G., Walker J., Warne G., Wiesemann C., Wisniewski A., Witchel S., Zieselman K.Fuentes:scopusTildacerfont in Adults with Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
ArticleAbstract: Context: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treatePalabras claves:17-hydroxyprogesterone, adrenocorticotropic hormone, androstenedione, Congenital adrenal hyperplasia, CRF-receptor antagonist, tildacerfontAutores:Barnes C.N., Huang M., Imel E.A., Madu I.J., Merke D.P., Moriarty D., Nakhle S., Newfield R.S., Richard J. Auchus, Sarafoglou K., Vogiatzi M.G.Fuentes:scopus